[go: up one dir, main page]

PT1264599E - Tnf-derived peptides for use in treating oedema - Google Patents

Tnf-derived peptides for use in treating oedema Download PDF

Info

Publication number
PT1264599E
PT1264599E PT02077256T PT02077256T PT1264599E PT 1264599 E PT1264599 E PT 1264599E PT 02077256 T PT02077256 T PT 02077256T PT 02077256 T PT02077256 T PT 02077256T PT 1264599 E PT1264599 E PT 1264599E
Authority
PT
Portugal
Prior art keywords
tnf
oedema
alpha
present
derived peptides
Prior art date
Application number
PT02077256T
Other languages
Portuguese (pt)
Inventor
Rudolf Lucas
Patrick De Baetselier
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Rudolf Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Lucas filed Critical Rudolf Lucas
Publication of PT1264599E publication Critical patent/PT1264599E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to the finding that peptides derived from a specific domain of tumor necrosis factor-alpha (TNF- alpha ) can efficiently be used to treat oedema. More specifically, the present invention relates to the usage of peptides derived from the region of human TNF- alpha from Ser<100> to Glu<116> to treat pulmonary oedema. Moreover, the present invention concerns a circularized peptide having amino acid sequence CGQRETPEGAEAKPWYC which is very efficient in inducing oedema resolution.
PT02077256T 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema PT1264599E (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
PT1264599E true PT1264599E (en) 2008-01-07

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02077256T PT1264599E (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Country Status (20)

Country Link
US (2) US20030105021A1 (en)
EP (3) EP1105152A1 (en)
JP (1) JP4542266B2 (en)
CN (1) CN1181886C (en)
AT (2) ATE395072T1 (en)
AU (1) AU764992B2 (en)
BR (1) BR9912899A (en)
CA (1) CA2334941C (en)
CZ (1) CZ302862B6 (en)
DE (2) DE69938743D1 (en)
DK (1) DK1264599T3 (en)
ES (1) ES2296872T3 (en)
HU (1) HU227661B1 (en)
IL (2) IL141064A0 (en)
NZ (1) NZ509604A (en)
PL (1) PL203706B1 (en)
PT (1) PT1264599E (en)
TR (1) TR200100338T2 (en)
WO (1) WO2000009149A1 (en)
ZA (1) ZA200100656B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100338T2 (en) 1998-08-14 2001-12-21 Innogenetics N.V. TNF-derivatives peptides used in edema treatment.
DE602005019416D1 (en) * 2004-08-06 2010-04-01 Nycomed Gmbh COMPOSITION OF A PULMONARY SURFACTANT AND A TNF-DERIVED PEPTIDE
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (en) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick CYCLIC AND CYSTONE FREE PEPTIDE
AT506151B1 (en) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick FUSION PROTEIN
AT507953B1 (en) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh METHOD FOR AVOIDING AND TREATING HYPERPERMEABILITY
AT509267A1 (en) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh ORGANIC COMPOUNDS FOR THE REGULATION OF VECTOR ION CHANNELS
DK2397151T3 (en) * 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (en) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh COMPOSITION COMPRISING A PEPTIDE AND AN INHIBITOR OF VIRAL NEURAMINIDASE
EP2679239A1 (en) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmaceutical compound for treating the pulmonary form of altitude sickness caused by oxygen deprivation and reduced air pressure
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
JP6335279B2 (en) * 2013-04-23 2018-05-30 アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
MX2016011881A (en) 2014-03-18 2016-12-05 Apeptico Forschung & Entwicklung Gmbh Dry-powder peptide medicament.
CN110613838A (en) * 2018-06-19 2019-12-27 姜石松 Polypeptide for enhancing cell permeability and application thereof
IL317123A (en) 2018-08-27 2025-01-01 Regeneron Pharma Use of Raman Spectroscopy in Downstream Purification
EP4051307B1 (en) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptide for prevention or treatment of covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (en) * 1921-04-07 1923-10-27 Ludwig Weil Dr Impeller for centrifugal pumps and blowers
DE3841759A1 (en) 1988-12-12 1990-06-13 Basf Ag NEW TNF PEPTIDES
AU6001094A (en) 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
TR200100338T2 (en) 1998-08-14 2001-12-21 Innogenetics N.V. TNF-derivatives peptides used in edema treatment.

Also Published As

Publication number Publication date
US20030105021A1 (en) 2003-06-05
EP1247531A2 (en) 2002-10-09
BR9912899A (en) 2001-05-08
JP2002522508A (en) 2002-07-23
PL203706B1 (en) 2009-11-30
HUP0103117A2 (en) 2001-12-28
US7258861B2 (en) 2007-08-21
IL141064A (en) 2009-09-01
PL345997A1 (en) 2002-01-14
ES2296872T3 (en) 2008-05-01
HU227661B1 (en) 2011-10-28
US20030185791A1 (en) 2003-10-02
DK1264599T3 (en) 2008-02-04
CZ2001538A3 (en) 2001-08-15
EP1264599B1 (en) 2007-09-26
EP1264599A1 (en) 2002-12-11
CN1312724A (en) 2001-09-12
EP1247531B1 (en) 2008-05-14
EP1105152A1 (en) 2001-06-13
HUP0103117A3 (en) 2004-03-01
JP4542266B2 (en) 2010-09-08
HK1051805A1 (en) 2003-08-22
CZ302862B6 (en) 2011-12-21
WO2000009149A1 (en) 2000-02-24
AU5620999A (en) 2000-03-06
DE69937206D1 (en) 2007-11-08
ATE374039T1 (en) 2007-10-15
CN1181886C (en) 2004-12-29
IL141064A0 (en) 2002-02-10
CA2334941A1 (en) 2000-02-24
ZA200100656B (en) 2005-06-29
DE69938743D1 (en) 2008-06-26
CA2334941C (en) 2011-08-09
NZ509604A (en) 2003-05-30
ATE395072T1 (en) 2008-05-15
TR200100338T2 (en) 2001-12-21
DE69937206T2 (en) 2008-06-19
EP1247531A3 (en) 2002-12-18
AU764992B2 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
IL141064A0 (en) Tnf-derived peptides for use in treating oedema
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
IL187907A0 (en) Analogues of glp-1 and uses thereof
IL143481A0 (en) Glp-1 analogues
JP2001520045A5 (en)
EP0188400A3 (en) Oligopeptides, intermediates and process for their preparation
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO2002015922A3 (en) New uses for amino acid anticonvulsants for treatment of pain
ATE350396T1 (en) PEPTIDES DERIVED FROM NEUROFILAMENT PROTEINS AND THEIR MEDICAL USE
GB2367061A (en) Peptides
AR002742A1 (en) ADIPOSE TYPE REGULATORY PROTEIN, PROCEDURE TO PRODUCE SUCH PROTEIN, PHARMACEUTICAL FORMULATIONS INCLUDING IT, ISOLATED DNA MOLECULES THAT CODES SUCH PROTEIN, VECTOR AND RECOMBINANT CELLS THAT INCLUDE SUCH DNA
GR3015817T3 (en) Substituted alpha-amino acids having pharmaceutical activity.
WO1997046686A3 (en) Tumor necrosis factor-related polypeptide
ATE198987T1 (en) TREATMENT OF TROPICAL SPASTIC PARESIS WITH PEPTIDES T
BG102814A (en) New derivatives of carboxylic acid, their preparation and application
DE69524415D1 (en) UNSPLEATED VARIANTS OF THE GP350 / 220
DE69734644D1 (en) CARBOXYPEPTIDASES FROM ASPERGILLUS ORYZAE AND THESE ENCODING NUCLEIC ACIDS
WO1996003122A3 (en) Use of gabapentin in the treatment of anxiety and panic
DE50006409D1 (en) INJECTION SOLUTION CONTAINING A GOLD COMPOUND, CALENDULA AND BELLADONNA EXTRACTS FOR TREATING ARTHROSIS